MS and Brain Volume: Can Early Treatment Slow Brain Volume Loss?
"A new study explores the link between early interferon beta-1a treatment, brain volume, and disease activity in multiple sclerosis patients, offering insights for managing long-term brain health."
Multiple sclerosis (MS) is a chronic condition where the immune system attacks the protective sheath (myelin) covering nerve fibers, causing communication problems between the brain and the rest of the body. This can lead to a range of symptoms, including fatigue, difficulty walking, numbness, and vision problems. While there's currently no cure for MS, treatments can help manage symptoms and slow the progression of the disease.
One area of concern in MS is brain volume loss, also known as brain atrophy. Research has shown that people with MS can experience a greater rate of brain volume loss compared to healthy individuals. This loss of brain volume is linked to the accumulation of physical disability and cognitive decline over time. Therefore, finding ways to minimize brain volume loss is a critical goal in MS management.
A recent study published in the Journal of Clinical Neuroscience investigated the impact of early treatment with interferon beta-1a on brain volume loss in patients with relapsing-remitting MS (RRMS). The study aimed to determine whether early intervention could help slow down brain atrophy and improve long-term outcomes. This article explores the study's findings and what they mean for people living with MS.
Brain Volume Loss as a Disease Marker
Whole-brain atrophy in MS is reported at about 0.5–1% per year, making reliable detection of subtle volume changes important pmc.ncbi.nlm.nih.gov. Brain volume loss is emerging as a biomarker of disease progression and treatment response that complements conventional lesion-based measures sciencedirect.com. Research has also examined how loss rates change across stages of relapsing-remitting MS and how they relate to clinical measures and treatment escalation .
Measuring Brain Volume Loss
MRI-based brain volume loss measurement uses direct, segmentation-based techniques or indirect, registration-based techniques. There is no reference-standard technique, making it difficult to assess the accuracy and reliability of available algorithms pmc.ncbi.nlm.nih.gov. Applying volumetry in routine practice is also limited by measurement errors associated with using different MRI scanners across and within centers frontiersin.org. A cohort study has assessed the dynamics of brain volume loss after MS onset and the repeatability of estimates from two MRI protocols .
Brain Volume Loss Across MS
A 2015 review set out to systematically summarize reported rates of brain volume loss in MS and examine their associations with markers of disease severity sciencedirect.com. Brain-volume loss is described as multifactorial, arising from inflammatory focal axonal damage and myelin-sheath depletion, secondary neuroaxonal degeneration, and other immunologically triggered neurotrophic disturbances pmc.ncbi.nlm.nih.gov. It can occur across MS subtypes and is observable even in early stages pmc.ncbi.nlm.nih.gov.
Interferon Beta-1a and NEDA: A Closer Look
The study followed 87 RRMS patients for three years, all of whom were treated with interferon beta-1a, a common medication used to reduce the frequency and severity of MS attacks. The researchers tracked brain volume changes using MRI scans and assessed disease activity based on three factors: relapses, disability progression, and new or enlarged lesions on MRI. They then categorized patients into two groups: those who achieved No Evidence of Disease Activity (NEDA) and those who did not.
- Three-month confirmed disability progression, indicated by an increase in the Expanded Disability Status Scale (EDSS) score.
- Confirmed relapses or MS attacks.
- New or enlarged T2 lesions and/or gadolinium-enhancing (Gd+) lesions on MRI.
Early Disease Control and Long-Term Outcomes
One study reports that brain volume loss in MS can slow to the rate of normal aging once inflammatory disease activity has been extinguished; its authors advocate early introduction of high-efficacy disease-modifying therapy to reduce future disability risk doi.org. A real-world study of self-injectable DMTs concludes that NEDA-3 may be an effective early predictor of progression-free status at treatment follow-up of up to 10 years doi.org.
Comparing Treatment Effects
A 2025 review notes that multiple MS treatments have reduced brain volume loss in randomized controlled trials, but comparing their relative effectiveness is challenging because head-to-head comparisons are limited thelancet.com. It also reports that the relationship between treatment effects on brain volume loss and disability accumulation is not established for newer treatments thelancet.com. A 2024 systematic literature review identified brain-volume-loss results for disease-modifying treatments in relapsing MS, where brain volume loss is described as a predictor of disability progression and an emerging clinical-trial endpoint link.springer.com. An earlier review reports that interferon beta-1b reduced relapse rates and had a slight positive effect on progression in still-active secondary progressive MS .
What Does This Mean for MS Patients?
This study provides valuable insights into the importance of early and effective treatment for MS. The findings suggest that initiating treatment with interferon beta-1a early in the course of RRMS may help slow down brain volume loss, especially in patients who achieve NEDA. This highlights the importance of working closely with a neurologist to develop a personalized treatment plan and closely monitor disease activity.
Brain Volume as a Future Trial Measure
A December 2025 report says specific disease-modifying therapies significantly slow brain volume loss in adults with MS and links this benefit to reduced long-term disability multiplesclerosisnewstoday.com. A second report says researchers concluded that measuring brain volume loss should play an important role in future clinical trials aimed at reducing long-term disability ms-uk.org. Together, these reports point to brain-volume measurement as a potential focus for evaluating long-term treatment outcomes.
Real-World Brain and Disability Measures
A real-world cohort study compared lesion counts and volumes, along with various brain volumes, across groups of people with MS using the “md brain” software link.springer.com. A separate ongoing multicenter, prospective observational study is investigating whether changes in brain MRI biomarkers are associated with disability progression independent of relapse activity (PIRA) link.springer.com. That study reports a total of 453 participants link.springer.com.
It's important to note that this study focused on a specific treatment (interferon beta-1a) and a specific population (RRMS patients with early-stage disease). More research is needed to determine whether these findings apply to other treatments and other types of MS. However, the study adds to the growing body of evidence that supports the benefits of early intervention in MS.
Ultimately, the goal of MS treatment is to minimize the long-term impact of the disease on brain health and overall quality of life. By working with healthcare professionals and actively managing their condition, people with MS can take steps to protect their brains and live full and active lives.